Evidence map›Paper›PMID 39356325›Full record

Trial reportEuropean archives of psychiatry and clinical neuroscience2024

Effects of cognitive training and group psychotherapy on cognitive performance of post COVID-19 patients: an exploratory and non-randomized clinical trial.

Tarek Jebrini, Anabel Thomas, Simone Sachenbacher, Fides Heimkes, Susanne Karch, Stephan Goerigk, Michael Ruzicka, Gerardo Jesus Ibarra Fonseca, Nora Wunderlich, Christopher Benesch and 6 more

Abstract readClinical Trial
In one paragraph

Trial report in European archives of psychiatry and clinical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tarek JebriniDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany. tarek.jebrini@med.uni-muenchen.de.ORCID http://orcid.org/0009-0006-6523-7633
Anabel ThomasDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.
Simone SachenbacherDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.
Fides HeimkesDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.
Susanne KarchDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.
Stephan GoerigkDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.ORCID http://orcid.org/0000-0002-3021-0346
Michael RuzickaDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-2451-1070
Gerardo Jesus Ibarra FonsecaDepartment of Medicine IV, University Hospital, LMU Munich, Munich, Germany.
Nora WunderlichDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.
Christopher BeneschDepartment of Medicine II, University Hospital, LMU Munich, Munich, Germany.
Anna PernprunerDepartment of Medicine II, University Hospital, LMU Munich, Munich, Germany.
Bernhard HeindlStabstelle Strategische Unternehmenssteuerung, LMU Munich, Munich, Germany.
Hans Christian StubbeDepartment of Medicine II, University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-7873-996X
Aline Olivia UebleisDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.
Fabienne Grosse-WentrupDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstraße 7, 80336, Munich, Germany.
Kristina AdorjanDepartment of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0001-7501-9556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive complaints are common signs of the Post COVID-19 (PC) condition, but the extent and type of cognitive impairment may be heterogeneous. Little is known about neuropsychological treatment options. Preliminary evidence suggests cognitive symptoms may improve with cognitive training and naturally over time. In this clinical trial, we examined whether participation in a weekly group consisting of cognitive training and group psychotherapy is feasible and would exert beneficial effects on cognitive performance in PC and whether improvements were associated with intervention group participation or represented a temporal improvement effect during syndrome progression. 15 PC patients underwent an 8-week intervention. Cognitive performance was assessed before and after each intervention group participation. A control group of 15 PC patients with subjective neurocognitive or psychiatric complaints underwent two cognitive assessments with comparable time intervals without group participation. To attribute changes to the intervention group participation, interaction effects of group participation and time were checked for significance. This is an exploratory, non-randomized, non-blinded controlled clinical trial. Within the intervention group, significant improvements were found for most cognitive measures. However, significant time x group interactions were only detected in some dimensions of verbal memory and visuo-spatial construction skills. Significant time effects were observed for attention, concentration, memory, executive functions, and processing speed. The intervention setting was feasible and rated as helpful and relevant by the patients. Our results suggest that cognitive symptoms of PC patients may improve over time. Patients affected by both neurocognitive impairments and mental disorders benefit from group psychotherapy and neurocognitive training. The present study provides evidence for a better understanding of the dynamic symptomatology of PC and might help to develop further studies addressing possible therapy designs. The main limitations of this exploratory feasibility trial are the small sample size as well as the non-randomized design due to the clinical setting.

Indexed as

Cognitive Behavioral TherapyCognitive DysfunctionCOVID-19Psychotherapy, GroupAdultAgedCognitive TrainingFemaleHumansMaleMiddle AgedNeuropsychological TestsPost-Acute COVID-19 SyndromeTreatment OutcomeCognitive impairmentCognitive trainingGroup psychotherapyPost-COVID syndrome

Identifiers

PMID39356325
PMCPMC11579059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.